Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
March 8, 2022 09:44 AM ESTUpdated March 11, 02:56 AM
Bioregnum

‘We would have no choice’: Bio­gen CEO Vounatsos isn’t about to let go of the bud­get axe — un­less they break that los­ing streak

Bio­gen CEO Michel Vounatsos is bet­ting on suc­cess. But he’s keep­ing one hand firm­ly on the bud­get axe in case the cards stay cold. And …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times